Results 111 to 120 of about 11,081 (214)
Pediatric Obesity, Volume 21, Issue 6, June 2026.ABSTRACT Background Evidence for the role of health behaviour and lifestyle treatment (HBLT) on the effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in paediatric obesity is limited. Objectives To assess the role of HBLT on the effectiveness of GLP‐1RAs in youth with obesity.
Julia Lischka +17 more
wiley +1 more source
Acute pancreatitis following orlistat therapy: report of two cases
, 2010 Context: Orlistat is a pancreatic lipase inhibitor licensed for the treatment of obesity. As obesity rates increase and non-prescription dispensing of orlistat increases, an awareness of its adverse effects is of crucial importance as complications arise
Mahmud, Sajid, Ahmad, Faheem Asem
core
Nutrición Hospitalaria, 2011 Introduction: The prevalence of obesity, a serious public health problem, is increasing among teenagers and thus also increases cardiovascular morbidity and mortality in adulthood.
E. García Díaz, T. Martín Folgueras
doaj
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2001 H, Chabrol, G, Péresson, S, Callahan
openaire +2 more sources
Orlistat reduziert die Gallenblasenmotilität durch Verminderung der Cholecystokinin-Serumspiegel
, 2004 \(\bf {Problem:}\) Orlistat ist ein kovalenter Hemmstoff intestinaler Lipasen, der die Triglyceridhydrolyse um 30% vermindert. Der Einfluß von Orlistat auf die Gallenblasenmotilität und auf die Sekretion von CCK wurde untersucht.
Ellrichmann, Mark
core
Changes in Plasma Leptin Levels in Men in Response to Aerobic Training, and Using Orlistat
مجله دانشکده پزشکی اصفهان, 2017 Background: Obesity is a complex disorder with excessive accumulation of adipose tissue; the tissue that exudes leptin, a hormone which plays an important role in the regulation of cellular metabolism and energy balance.
Abazar Teimoori +3 more
doaj
, 2007 Unconjugated hyperbilirubinemia in Crigler-Najjar (CN) disease is conventionally treated with phototherapy and phenobarbital. Orlistat treatment increases fecal fat excretion and decreases plasma unconjugated bifirubin (UCB) concentrations in Gunn rats ...
Hafkamp, Anja M. +11 more
core +1 more source
MECHANISM OF ORLISTAT HYDROLYSIS BY FATTY ACID SYNTHASE THIOESTERASE
, 2012 poster abstractFatty acid synthase (FASN) is the sole protein capable of de novo synthesis of free fatty acids. The fatty acid synthesis cycle begins with the condensa-tion of acetyl-CoA and malonyl-CoA, and continues with the elongation of the fatty ...
Zhang, Jian-Ting, Liu, Jing-Yuan
core +1 more source
, 2001 The inhibition of digestive lipases by the antiobesity drug Orlistat along with lipolysis levels and fecal fat excretion were measured in healthy humans. Orlistat was found to be a powerful gastric lipase inhibitor, achieving 46.6–91.4% enzyme inhibition
René Laugier +13 more
core +1 more source
Orlistat-associated adverse effects and drug interactions: a critical review
, 2008 Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be aware that its use may be ...
Elisaf, M. S. +5 more
core